Avid Radiopharmaceuticals
Molly Johnson is a Clinical Trial Manager at Avid Radiopharmaceuticals, where responsibilities include guiding teams through product transitions, managing clinical trial protocols, and serving as an Informed Consent Subject Matter Expert. With experience as a Senior Clinical Research Associate and previous roles in clinical research, Molly has contributed to significant milestones, such as closing Phase III clinical trials for FDA approval. Additionally, Molly has a background in healthcare recruitment and teaching dance, emphasizing discipline and teamwork. Academic credentials include a Master's Degree in Biomechanics and Movement Science from the University of Delaware and a Bachelor's Degree in Kinesiology from Penn State University.
Avid Radiopharmaceuticals
1 followers
At Avid, a wholly owned subsidiary of Eli Lilly and Company, our mission is to develop new molecular imaging agents capable of changing the medical management of significant chronic human diseases. We have assembled an outstanding management team with extensive imaging and CNS development experience to help make pre-symptomatic disease detection a reality. Avid's pipeline of imaging compounds has the potential to dramatically alter the clinical course of challenging conditions such as Alzheimer's disease, Dementia with Lewy Bodies, Parkinson's disease and Diabetes Mellitus. This may be possible because our molecular imaging compounds may be able to detect the first stages of pathological change; allowing early treatment and management of people at risk - perhaps before before symptoms of disease can develop.